Grade My Investments
HomeFree Stock Grades › PRCT

PROCEPT BioRobotics Corporation (PRCT) Stock Grade

PRCT · Healthcare

A
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.7B
P/E Ratio
Revenue Growth (YoY)
+37.2%
Net Margin
-31.0%
Return on Equity
Dividend Yield
None

About PROCEPT BioRobotics Corporation's fundamentals

PROCEPT BioRobotics is a medical device company with a market capitalization of $1.7 billion that is experiencing strong revenue growth of 37.2% year-over-year, indicating expanding market adoption of its products. However, the company is currently unprofitable, operating at a net margin of -31.0% and reporting a net loss in its latest annual statement, meaning it is spending significantly more than it generates in revenue. The company does not pay a dividend and lacks traditional profitability metrics like price-to-earnings ratio and return on equity, reflecting its early-stage growth profile in the medical device sector.

Track PRCT free — no credit card required. Live grade + monthly AI report →